Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
2016-01-25
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects of giving bevacizumab together with
temsirolimus and to see how well it works in treating patients with recurrent or persistent
endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for their growth. Giving
bevacizumab together with temsirolimus may kill more tumor cells.